Sitemap - 2025 - The Oncology Shot with Timothee Olivier
Aging Out of Evidence: Why Cancer Trials Still Miss Older Adults
How To Study Drugs With Apparent Massive Effect Sizes, Still Using Randomization?
Placebo First, Treatment Later: Is This Fair to Patients With Active Cancer?
When the Follow-Up Ends Too Soon: Rethinking Long-Term Benefit of Immunotherapy
Are fears of rising cancer in young adults exaggerated? A live talk with Ade Adamson
The Iceberg Plot: A Visual I Conceived to Differentiate Tumor Biology from Treatment Effect.
Post-ESMO 2025 on Adjuvant CDK4/6 Inhibitors after MonarchE and NATALEE Updates.
Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.
Oncology “Me-Too” Drugs Compared With Original Drugs in Randomized Clinical Trials